Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults

• Published in: PloS one 2021-01, Vol.16 (1), p.e0244947-e0244947
• Main Authors: Salyani, Adil, Shah, Jasmit, Adam, Rodney, Otieno, George, Mbugua, Evelyn, Shah, Reena
• Format: Article
• Language: English
• Subjects: Adult; Adults; Alanine; Alanine transaminase; Antibodies; Antigens; Antiretroviral therapy; Aspartate aminotransferase; Asymptomatic Infections - epidemiology; Biology and life sciences; Blood platelets; CD4 antigen; Coinfection - epidemiology; Coinfection - virology; Core protein; Cross-Sectional Studies; Demographics; Deoxyribonucleic acid; DNA; Female; Gene expression; Hepatitis; Hepatitis B; Hepatitis B - complications; Hepatitis B - epidemiology; Hepatitis B - virology; Hepatitis B core antigen; Hepatitis B surface antigen; Hepatitis B Surface Antigens - blood; HIV; HIV Infections - complications; HIV Infections - virology; Hospitals; Human immunodeficiency virus; Humans; Immunization; Immunoassay; Infections; Kenya - epidemiology; Laboratories; Male; Medical records; Medicine; Medicine and health sciences; Mortality; People and Places; Prevalence; Public health; Sample size; Statistical analysis; Vaccination; Vaccines; Viruses
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0244947

Occult hepatitis B virus (HBV) infection (OBI) is a phase of HBV infection characterised by the presence of HBV DNA in the absence of detectable hepatitis B surface antigen (HBsAg). OBI is of concern in the HIV-infected due to high prevalence and risk of HBV reactivation. The prevalence and clinico-demographic characteristics of OBI in anti-retroviral therapy (ART) naïve HIV infected adults in Kenya is unknown. A cross sectional study carried was out at three sites in Kenya. HIV infected ART naïve adults were enrolled and demographic data collected. Blood samples were assayed for HBsAg, HBV DNA, alanine aminotransferase, aspartate aminotransferase, antibodies to hepatitis B surface antigen (anti-HBs) and hepatitis B core antigen (anti-HBc). Data on CD4 count, HIV viral load and platelet count were obtained from medical records. Of 208 patients, 199 (95.7%) did not report HBV vaccination, 196 (94.2%) were HBsAg negative, 119 (57.2%) had no HBV markers, 58 (27.9%) had previous HBV infection (anti-HBc positive) and 11 (5.3%) had OBI. All 11 (100%) OBI patients were anti-HBc positive. OBI patients comprised 19.0% of HBsAg negative, anti-HBc positive patients. There was no difference in clinico-demographic characteristics between the overt HBV, OBI and HBV negative patients. This was the first study on OBI in ART naïve HIV infected adults in Kenya. The lower OBI prevalence compared to other sub-Saharan African countries could be attributed to lower HBV exposure. Most patients were HBV unexposed and unimmunized, outlining the need to implement guideline recommended immunization strategies.